PubRank

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Clinical Trial ID NCT01193244

PubWeight™ 33.86‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01193244

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
2 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
3 Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015 1.79
4 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
5 Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 2013 1.26
6 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
7 Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016 1.21
8 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
9 Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl 2013 1.11
10 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014 1.11
11 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
12 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
13 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
14 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
15 Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011 0.94
16 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
17 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
18 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
19 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
20 Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014 0.86
21 Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013 0.85
22 Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol 2012 0.84
23 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
24 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
25 Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014 0.82
26 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
27 Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013 0.78
28 Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis. Clin Pharmacol Ther 2015 0.78
29 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
30 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
31 Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer. Front Endocrinol (Lausanne) 2012 0.76
32 The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. P T 2012 0.75
33 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
34 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
Next 100